Bridgeway Capital Management, LLC Altimmune, Inc. Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.22 - $13.81 $226,872 - $381,156	-27,600 Reduced 44.73%	34,100 $347,000
Q4 2023 Feb 14, 2024	SELL	$2.14 - $11.62 $149,800 - $813,400	-70,000 Reduced 53.15%	61,700 $694,000
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $454,365 - $786,249	131,700 New	131,700 $464,000
Q1 2021 May 17, 2021	SELL	$12.71 - $24.31 $353,338 - $675,818	-27,800 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $39,200 - $71,100	-5,000 Reduced 15.24%	27,800 $314,000
Q3 2020 Nov 16, 2020	SELL	$9.93 - $33.26 $57,594 - $192,908	-5,800 Reduced 15.03%	32,800 $433,000
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $7,250 - $26,775	2,500 Added 6.93%	38,600 $413,000
Q4 2019 Feb 14, 2020	BUY	$1.53 - $2.15 $55,233 - $77,615	36,100 New	36,100 $68,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $353M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.